Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02015117 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 88 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 2 entries Completion pushed from Oct 8, 2026 to Sep 23, 2027 · Eligibility criteria shortened, about 10 words · Secondary endpoints: details revised at 2 of 6 entries Show 3 more changesShow less
    • Completion pushed from Oct 8, 2026 to Sep 23, 2027
    • Eligibility criteria shortened, about 10 words
    • Secondary endpoints: details revised at 2 of 6 entries
  2. 13 versions Re-verified since Mar 24, 2026, no change to tracked fieldsv75-v87
  3. Completion date: Oct 8, 2025 to Oct 8, 2026v74
  4. 3 versions Re-verified since Mar 25, 2025, no change to tracked fieldsv71-v73
  5. Completion date: Sep 27, 2024 to Oct 8, 2025v70
Show 31 earlier versionsHide 31 earlier versions
  1. 4 versions Re-verified since Nov 7, 2023, no change to tracked fieldsv66-v69
  2. Primary completion date: Dec 31, 2016 to Jul 10, 2020 Start date: Jan 8, 2014 to Apr 28, 2014 · Completion date: Sep 27, 2024v65 Show 2 more changesShow less
    • Start date: Jan 8, 2014 to Apr 28, 2014
    • Completion date: Sep 27, 2024
  3. 3 versions Re-verified since Oct 15, 2022, no change to tracked fieldsv62-v64
  4. Study sites: 2 to 1v61
  5. Study sites: 1 to 2v60
  6. 13 versions Re-verified since Mar 8, 2018, no change to tracked fieldsv47-v59
  7. Secondary endpoints reorderedv46
  8. Secondary endpoints revised (6)v45 See this version in full on ClinicalTrials.gov ↗
  9. 6 versions Re-verified since Aug 11, 2017, no change to tracked fieldsv39-v44
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial studies the side effects and best dose of trametinib with or without whole brain radiation therapy in treating patients with brain metastases. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs, such as trametinib, may make tumor cells more sensitive to radiation therapy. Giving trametinib with whole brain radiation therapy may be a better treatment for brain metastases.
Trial Details
NCT Number NCT02015117
Lead Sponsor National Cancer Institute (NCI)
Conditions Metastatic Malignant Neoplasm in the Brain
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov